Abstract Long-term surviving recipients of allogeneic hematopoietic stem cell transplantation (HSCT) often suffer from diabetes mellitus (DM). We sought to identify risk factors for the development of post-transplant DM and impaired glucose tolerance (IGT) in pediatric HSCT patients. Glucose tolerance statuses were evaluated in 22 patients aged 6.3-21.8 years who had received allogeneic HSCT between the ages of 0.8-13.5 years. Five patients were diagnosed as having type 2 DM, and treated with insulin or oral hypoglycemic agents. Five patients were included in the IGT group, and the remaining 12 children were in the normal glucose tolerance (NGT) group. The cumulative incidence of DM plus IGT was 11.6 % at 5 years and 69.3 % at 10 years. None of the patients were obese/overweight and none had a family history of DM. There were no significant differences in serum levels of leptin and adiponectin between the DM ? IGT and the NGT groups. An average preprandial glucose levels in the DM ? IGT group were significantly higher than those in the NGT group from preparative conditioning to 60 days after HSCT. In multivariate analysis, an age of C6 years at the time of HSCT was significantly associated with the development of DM ? IGT. Additionally, careful followup is necessary, even for NGT patients.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for childhood hematological malignancies [1] . Most long-term survivors of allogeneic HSCT, however, experience transplant-related sequelae, particularly endocrine disorders [2, 3] . In recent years, patients who had undergone allogeneic HSCT during childhood or adolescence have been reported to develop diabetes mellitus (DM) [2] [3] [4] [5] [6] [7] [8] [9] [10] . In young adults, DM onset could worsen the long-term quality of life, because these patients might suffer from the early appearance of complications, such as cardiovascular disease. Taskinen et al. [5] found that the variables associated with hyperinsulinemia in bone marrow transplantation (BMT) patients were the time from transplantation, the presence of chronic graftversus-host disease (GVHD), and hypogonadism. On the other hand, Hoffmeister et al. [4] reported that the risk factors for type 2 DM in pediatric HSCT (autologous, syngeneic, and allogeneic) survivors were a diagnosis of acute or chronic leukemia, race/ethnicity other than nonHispanic white, family history of DM, and asparaginase toxicity. Armenian et al. [11] demonstrated that grade II-IV acute GVHD and total body irradiation (TBI) conditioning were associated with an increased risk of DM in autologous and allogeneic HSCT recipients (from infants to elderly patients). Accordingly, there are controversies regarding the risk factors associated with post-HSCT DM. In this study, we assessed glucose tolerance in patients who underwent pediatric allogeneic HSCT and attempted to identify the risk factors associated with abnormal glucose metabolism.
Patients and methods

Patients
We retrospectively examined the medical records of 22 patients who underwent allogeneic HSCT between 1996 and 2010 at the Department of Pediatrics, Shinshu University Hospital. The criteria for participation in this study included the following: a period of C2 years after allogeneic HSCT; ongoing follow-up at the Department of Pediatrics, Shinshu University Hospital; and the performance of glucose tolerance statuses of patients. An oral glucose tolerance test (OGTT) was performed on 21 patients. Patient demographics and details are provided in Tables 1 and 2 . The underlying diseases were acute lymphoblastic leukemia (n = 7), acute myeloid leukemia (n = 11), mixed lineage leukemia (n = 2), juvenile myelomonocytic leukemia (n = 1), and blastic NK cell lymphoma (n = 1). The median ages at diagnosis and at the first allogeneic HSCT were 5.1 years (range 0.4-10.5 years), and 7.4 years (range 0.8-13.5 years), respectively. The median age at the glucose tolerance status evaluation was 14.1 years (range 6.3-21.8 years), and the median duration from the first allogeneic HSCT to the evaluation was 5.9 years (range 2.0-14.7 years). No patients had asparaginase toxicity.
The study protocol was approved by the institutional review board of The Shinshu University School of Medicine, and written informed consent was obtained from the parents and the patients themselves if patient age was C16 years of age.
Transplantation procedure
The conditioning regimen for each patient is shown in Table 2 . Patient no. 10 underwent prophylactic cranial irradiation at an 18-Gy dose 6 years before allogeneic HSCT. Twenty-one patients received TBI-based preparative conditioning for a first allogeneic HSCT (16 patients, 8 Gy; 1 patient, 10 Gy; and 4 patients, 12 Gy). Patient no. 7 received a busulfan-based conditioning regimen. Patient no. 22 received a 7-Gy craniospinal irradiation and a 3-Gy whole-brain irradiation 5 months after undergoing 8-Gy TBI. Three of the 22 patients underwent C2 allogeneic HSCTs. For the second and third HSCTs in patients no. 5 and 21, we performed chemotherapy alone as preparative conditioning. Chemotherapy combined with local 20-Gy irradiation (orbital cavity) was used as conditioning before the second allogeneic HSCT in patient no. 19.
Donors
Human leukocyte antigens (HLA) for A, B, and DRB1 in donors as well as recipients were determined by highresolution DNA typing. The stem cell source and HLA disparity in each HSCT is described in detail in Table 2 . For 3 patients (no. 5, 19, and 21) who underwent multiple allogeneic HSCTs, the donors were relatives of the patients. In the remaining 19 patients, the stem cell sources were relative BM (n = 6), non-relative BM (n = 3), relative peripheral blood (PB, n = 4), and non-relative cord blood (CB, n = 6).
Prophylaxis for GVHD
As a prophylactic treatment for GVHD, cyclosporin A and short-term methotrexate (sMTX) was used in 6 cases, tacrolimus ? sMTX ? methylprednisolone (mPSL) in 18 cases, and sMTX alone in 2 cases.
Anthropometric measurements
After measuring the body weight and height, the body mass index (BMI) was calculated by dividing the body weight in kilograms by the squared body height in meters (kg/m 2 ). For patients aged \17.5 years, the BMI percentile was determined with the calculation software invented by a joint committee on growth reference values, The Japanese Society for Pediatric Endocrinology, and the Japanese Association for Human Auxology (http://jspe.umin.jp/tai kakushisuv1.xlsx). Patients with a BMI of C90th percentile according to age and gender were classified as overweight or obese. For patients aged C17.5 years, patients with BMIs of C25 and C30 kg/m 2 were classified as overweight and obese, respectively, according to the definitions from the World Health Organization [12] .
Evaluation of glucose tolerance status
The insulin, hemoglobin A1c (HbA1c), and fasting plasma glucose levels were measured. During the acute phase after allogeneic HSCT, the blood glucose levels were measured daily or once every few days, early in the morning before meals. We then counted the number of times that the preprandial blood glucose levels exceeded 150 mg/dL from 30 days before the start of preparative conditioning to 60 days after HSCT in each patient, because the shortest length of hospital stay was 62 days after HSCT.
The HbA1c levels were expressed as National Glycohemoglobin Standardization Program equivalent values (%) and were calculated with the formula HbA1c = HbA1c (Japanese Diabetes Society) (%) ? 0.4 % [13] .
The glucose tolerance statuses of 21 patients were evaluated using the OGTT. After an overnight fast, 1.75 g/ kg (maximum of 75 g) of glucose were orally administered. The plasma glucose and insulin levels were measured in blood samples that were collected before and at 15, 30, 60, 90, and 120 min after the glucose loading. OGTT was performed once in 17 patients, and repeated OGTT was done in 4 patients.
The definitions of DM, impaired fasting glucose, and impaired glucose tolerance (IGT) were formulated on the basis of the diagnostic criteria established in 2010 by the American Diabetes Association [14] . Briefly, DM was defined as an HbA1c of C6.5 %, a fasting plasma glucose level of C126 mg/dL, a plasma glucose level of C200 mg/ dL at 2 h after an OGTT, or classic symptoms of hyperglycemia/hyperglycemic crisis with a random plasma glucose level of C200 mg/dL. Impaired fasting glucose was defined as a fasting plasma glucose level of 100-125 mg/ dL. IGT was defined as a plasma glucose level of 140-199 mg/dL at 2 h after an OGTT. A group of patients who did not satisfy the criteria for DM, impaired fasting glucose, and IGT were defined as the normal glucose tolerance (NGT) group. Insulin secretion, insulin resistance, and the sensitivity index were calculated as follows: the insulinogenic index = (Ins 30 -Ins 0 )/(Glu 30 -Glu 0 ), where Ins y and Glu y represent values at time y min during OGTT [15, 16] ; the homeostasis model assessment of insulin resistance (HOMA-IR) = Glu 0 9 Ins 0 /405 [15, 17] ; and the Matsuda insulin sensitivity index (ISI) = 10,000/(Glu 0 9 Ins 0 9 Glu 120 9 Ins 120 ) 0.5 [15, 18, 19] . HOMA-IR values [2.6 were considered diagnostic of insulin resistance [20] .
Measurement of serum adipocytokines
The serum leptin levels were measured with a doubleantibody radioimmunoassay. The adiponectin levels were measured with a latex turbidimetric immunoassay (SRL Inc., Tokyo, Japan).
Statistical methods PASW Statistics, Version 18.0 (SPSS, Inc., Chicago, IL, USA) was used for the statistical analyses. The MannWhitney test or unpaired t test was used to compare clinical parameters between the DM ? IGT and NGT groups, as well as between the IGT group and NGT groups. The cumulative incidence of DM ? IGT from allogeneic HSCT to the diagnosis day of DM or IGT was estimated according to the Kaplan-Meier method. To determine factors predictive of the development of DM ? IGT, the patients' parameters were analyzed with the Chi squared test or Fisher's exact test. Then, the parameters displaying p \ 0.1 in the univariate analysis were applied to logistic regression model. Statistical significance was defined as p \ 0.05.
Results
Glucose tolerance statuses of 22 patients who underwent pediatric allogeneic HSCT
The fasting blood glucose levels at the onset of hematological malignancies were within the normal range in all 22 patients. As presented in Table 3 , 5 patients were diagnosed with type 2 DM (DM group), on the basis of the diagnostic criteria by the American Diabetes Association [the fasting plasma glucose levels (C126 mg/dL) and HbA1c levels (C6.5 %)], upon evaluation at 4-12 years after allogeneic HSCT. According to the OGTT results, 4 patients had plasma glucose levels [200 mg/dL at 2 h after glucose loading. Patient no. 3 was classified into the DM group by the third OGTT. Patient no. 4 was treated with insulin, whereas the other 4 patients were treated with oral hypoglycemic agents. In cases no. 6-10, the plasma glucose levels at 2 h after glucose loading were C140 mg/dL, although the fasting plasma glucose levels were \100 mg/dL and the HbA1c levels were \6.5 %. Patient no. 8 was classified into the IGT group from the second OGTT. Accordingly, these five patients were included in the IGT group. Patients no. 11-22 had fasting plasma glucose levels \100 mg/dL, HbA1c levels \6.5 %, and normal responses to OGTT and were included in the NGT group. In patient no. 19, he showed IGT on the first OGTT during treatment with prednisolone, but displayed normal responses to the second and third OGTT without the steroid administration. Five patients with type 2 DM described above satisfied the diagnostic criteria by the Japan Diabetes Society (http://www.jds.or.jp/modules/en/index.php?con tent_id=1). Five patients classified as the IGT group and 12 patients classified as the NGT group corresponded to borderline type and normal type, respectively, according to the Japanese criteria. The cumulative incidence of DM ? IGT was 11.6 % at 5 years and 69.3 % at 10 years after HSCT.
All 5 patients in the DM group had a HOMA-IR of[2.6, and Matsuda ISI levels of 4 evaluated patients ranged from 1.7 to 2.9. The HOMA-IR levels of patient nos. 7, 14, and 15 were 3.4, 2.7, and 2.8, respectively. Seventeen patients were \17.5 years when the glucose tolerance statuses were evaluated. For these patients, the mean BMI percentile according to age and gender was 28.3. The remaining 5 patients were [17.5 years, and their mean BMI was 19.6. Thus, none of the patients in our study were obese or overweight.
Comparison of clinical findings between the DM ? IGT group and NGT group There were significant differences between the DM ? IGT group and NGT group with regard to the fasting plasma glucose levels (122.7 ± 46.2 vs. 89.3 ± 5.2, p \ 0.001), HbA1c levels (7.2 ± 2.1 vs. 5.5 ± 0.4, p = 0.029), fasting insulin levels (9.9 ± 3.1 vs. 6.3 ± 3.6, p = 0.018), HOMA-IR (3.0 ± 1.3 vs. 1.4 ± 0.8, p = 0.002), and Matsuda ISI (3.1 ± 1.1 vs. 8.9 ± 5.6, p = 0.001). The median age at diagnosis of hematological malignancies did not differ between the DM ? IGT group and NGT group, with values of 5.8 years (range 2.6-10.5 years) vs. 4.0 years (range 0.5-9.9 years), respectively. The median age at first allogeneic HSCT was higher in the DM ? IGT group than in the NGT group, with values of 9.1 years (range 5.0-13.6 years) vs. 5.3 years (range 0.8-12.6 years; p = 0.047), respectively. In addition, the median age at the glucose tolerance status evaluation was substantially higher in the DM ? IGT group than in the NGT group, with values of 16.1 years (range 9.6-21.9 years) vs. 9.7 years (range 6.3-18.3 years; p = 0.001), respectively. The median interval between allo-HSCT and glucose tolerance status assessment study was also longer in the DM ? IGT group than in the NGT group, with values of 78 months (range 32-176 months) vs. 60 months (range 24-90 months; p = 0.031), respectively.
We then compared the preprandial blood glucose levels in the morning from 30 days before the start of preparative conditioning to 60 days after HSCT between the DM ? IGT group and NGT group. There was no difference in the frequencies of blood sampling for 30 days before the start of preparative conditioning (10.6 ± 4.4 times in the DM ? IGT group vs. 10.4 ± 4.1 times in the NGT group, p = 0.923) and in the frequencies of blood sampling from the start of preparative conditioning to 60 days after HSCT (47.9 ± 14.6 times in the DM ? IGT group vs. 51.3 ± 9.9 times in the NGT group, p = 0.505). The prepandial blood glucose levels increased after the start of preparative conditioning in the DM ? IGT group, when compared with the values obtained before preparative conditioning (101.4 ± 13.1 vs. 117.8 ± 15.9 mg/dL, p \ 0.001), but not in the NGT group (95.4 ± 11.9 vs. 98.8 ± 13.8 mg/dL, p = 0.522). The mean prepandial blood glucose levels from the start of preparative conditioning to 60 days in the DM ? IGT group were significantly higher than those in the NGT group (p = 0.007), while there was no substantial difference in the values before the preparative conditioning between the two groups. Among 10 patients in the DM ? IGT group, 7 patients developed hyperglycemia (C150 mg/dL) 4-32 times, and one patient showed hyperglycemia twice. In the NGT group, 3 of 12 patients developed hyperglycemia (C150 mg/dL) 4-12 times, and 4 patients showed hyperglycemia once to three times. Hyperglycemic episodes occurred sporadically or successively in the both groups.
Risk factors for post-transplant DM ? IGT To examine whether patients who would develop DM or IGT could be predicted before and soon after allogeneic HSCT, we first performed univariate analysis of the patients' pre-transplant information and clinical data after HSCT (Table 4 ) When the patients were separated into younger (\6 years of age) and older groups (C6 years of age) at the time of allogeneic HSCT, DM ? IGT occurred more frequently in the older group than in the younger group (p = 0.026). Patients with C4 times of hyperglycemia during acute phase of HSCT were more frequently observed in the DM ? IGT group than in the NGT group (p = 0.046). Multivariate analysis showed C6 years of age at the time of HSCT as the only significant risk factor for the development of DM or IGT (p = 0.040). Repeated hyperglycemia was marginally associated with the occurrence of DM ? IGT (p = 0.056, Table 5 ).
On the other hand, there were no differences with regard to family history of DM and underlying diseases between the DM ? IGT group and NGT group. Two or three allelemismatched or unrelated HSCT did not influence DM ? IGT development. Grade II-IV acute GVHD, chronic GVHD, tacrolimus use for GVHD prophylaxis or treatment, and corticosteroid use over 4 weeks after allogeneic HSCT all failed to influence DM ? IGT development (Table 4) .
Relationship between adipocytokines and DM ? IGT development
The fasting/early morning serum leptin and adiponectin levels were measured in 19 cases. The leptin levels in the DM ? IGT and NGT groups were 14.0 ± 11.7 and 5.5 ± 3.0 ng/mL, respectively (p = 0.106), whereas the adiponectin levels were 8.3 ± 6.2 and 11.5 ± 3.6 lg/mL, respectively (p = 0.180).
Discussion
In the present study, the cumulative incidence of DM ? IGT in 22 allogeneic HSCT survivors was 11.6 % at 5 years and 69.3 % at 10 years. Among these patients, 21 received TBI (C8 Gy)-based preparative regimens. Similar results were reported by Taskinen et al. [5] , that 12 (52 %) of the 23 children who underwent BMT developed IR (DM in 4 and IGT in 6). The authors of that study used TBI (10-12 Gy) as conditioning for 18 patients. Neville et al. [21] described that TBI conditioning increased the risk of hyperinsulinemia/IGT/DM development, whereas busulfan was protective. Therefore, TBI regimens appear to frequently cause post-transplant insulin resistance.
DM causes various types of chronic complications such as cardiovascular disease, which particularly worsens patients' quality of life. Therefore, we attempted to identify the risk factors to promote the prevention of and/or early intervention for post-transplant DM and IGT. The multivariate analysis revealed C6 years of age at the time of HSCT as only a significant risk for post-transplant DM ? IGT. The more frequent occurrence of post-HSCT abnormal glucose metabolism after HSCT in the older patients might be related to the evidence that insulin resistance increases during adolescence [26, 27] . A large part of patients in the DM ? IGT group were older than 15 years at the time of the study, whereas only 2 of 12 patients in the NGT group were older than 15 years. Thus, we cannot deny a possibility that the older age at the time of HSCT in the DM ? IGT group reflected the older age at the time of the study.
In the current study, an average of preprandial blood glucose levels early in the morning during acute phase of HSCT was significantly higher in the DM ? IGT group than in the NGT group, although repeated hyperglycemia marginally associated with the development of DM ? IGT according to multivariate analysis. Seven of 10 patients in the DM ? IGT group experienced C4 episodes of hyperglycemia up to 60 days after HSCT. Sheean et al. [22, 23] described that hyperglycemia occurs frequently during the acute post-transplant period because of intravenous hyperalimentation, glucocorticoid and immunosuppressant administration for GVHD, and infection. Accordingly, frequent hyperglycemia during HSCT might affect a patient's insulin resistance and insulin secretion capacity. On the basis of the results of 1,175 adult HSCT recipients as reported by Hammer et al. [24] , 93 % subjects experienced hyperglycemia (blood glucose level C150 mg/dL) at least once during the acute phase after HSCT. However, most of the blood glucose abnormalities were transient. Even when the patients developed steroid-induced DM, hyperglycemia was generally improved by a decreased or discontinued corticosteroid dosage. Therefore, a wait-andsee approach was adopted in most cases. Fuji et al. [25] demonstrated that intensive glucose control reduced the incidences of infectious disease and organ dysfunction after allogeneic HSCT. A prospective study will be DM diabetes mellitus, FK tacrolimus, GVHD graft-versus-host disease, HLA human leukocyte antigen, HSCT hematopoietic stem cell transplantation, IGT impaired glucose tolerance, mPSL methylprednisolone, NGT normal glucose tolerance, sMTX short-term methotrexate, TBI total body irradiation required to elucidate whether post-transplant DM ? IGT can be alleviated with intensive glycemic control during the acute post-transplant period. In contrast to previous reports regarding the general population, none of our HSCT survivors who developed DM ? IGT were obese or overweight. These results agree with those described by Taskinen et al. [5] and Hoffmeister et al. [4] . Adipocytokines, such as leptin and adiponectin, which are produced and secreted by adipocytes, have been shown to be involved in insulin resistance development in obese subjects [28] . An increase in visceral fat causes a decrease in the blood adiponectin level, thus leading to insulin resistance [29] . By acting on receptors in the hypothalamus, leptin exerts a strong inhibitory effect on food intake and an enhancing effect on energy consumption; however, obese patients exhibit leptin resistance [30, 31] . Annaloro et al. [32] reported that adult patients who developed metabolic syndrome after undergoing HSCT had lower serum adiponectin levels and elevated serum leptin levels. On the other hand, there were no significant differences in the adiponectin and leptin levels between the DM ? IGT and NGT groups in our study. Taken together, these findings suggest that factors other than dysregulated adipocytokine production might be involved in the development of posttransplant DM ? IGT. Nevertheless, we cannot exclude the possibility of abdominal obesity in the DM ? IGT group.
Some patients in the NGT group showed elevated HOMA-IR values. In addition, patients in the NGT group were younger at the time of HSCT than those in the DM ? IGT group. While a majority of patients in the DM ? IGT group were in the adolescence or older at the time of the study, more than half of the NGT group were before puberty. Therefore, it is possible that the NGT group will develop IGT or DM later. Careful follow-up is necessary, even for NGT patients.
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